PMID- 27060359
OWN - NLM
STAT- MEDLINE
DCOM- 20171127
LR  - 20171201
IS  - 1613-4133 (Electronic)
IS  - 1613-4125 (Linking)
VI  - 60
IP  - 9
DP  - 2016 Sep
TI  - Urolithin A attenuates ox-LDL-induced endothelial dysfunction partly by 
      modulating microRNA-27 and ERK/PPAR-gamma pathway.
PG  - 1933-43
LID - 10.1002/mnfr.201500827 [doi]
AB  - SCOPE: Endothelial dysfunction and inflammation are both common events occurring 
      during the development of atherosclerosis. Previous studies have shown that 
      urolithins, the intestinal microflora metabolites of ellagitannin, exhibit 
      anti-inflammation and antioxidative properties. This study aims to investigate 
      the protective effect of urolithin A (UA) on ox-LDL-induced (where ox-LDL is 
      oxidized low-density lipoprotein) endothelial dysfunction and possible modes of 
      action. METHODS AND RESULTS: Human artery endothelial cells were incubated with 
      50 mug/mL ox-LDL and various concentrations of UA for 24 h. UA improved the 
      productions of nitric oxide and endothelial nitric oxide synthase in a 
      dose-dependent manner. UA markedly reduced the expressions of ICAM-1 
      (intercellular adhesion molecule 1) and MCP-1 (monocyte chemotactic protein 1) 
      and further attenuated THP-1 (human acute monocytic leukemia cell line) cell 
      adhesion. In addition, UA suppressed expressions of tumor necrosis factor alpha, 
      interleukin 6, and endothelin 1, and increased PPAR-gamma (peroxisome proliferators 
      activated receptor gamma) mRNA expression. Moreover, UA decreased miR-27 
      expression, and overexpression of miR-27 by adding pre-miR-27 abolished the 
      ability of UA to improve ox-LDL-induced PPAR-gamma decrease. Furthermore, UA 
      significantly downregulated phosphorylated ERK1/2 (where ERK is extracellular 
      signal-regulated kinase) while decreasing interleukin 6 level and elevating 
      PPAR-gamma. CONCLUSIONS: UA could alleviate endothelial dysfunction induced by ox-LDL 
      partially through modulating miR-27 expression and ERK/PPAR-gamma pathway.
CI  - (c) 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Han, Qi-An
AU  - Han QA
AD  - College of Food Science and Engineering, Northwest A&F University, Shaanxi, 
      China.
FAU - Yan, Chunhong
AU  - Yan C
AD  - School of Life Science and Technology, Xi'an Jiaotong University, Shaanxi, China.
FAU - Wang, Lingfang
AU  - Wang L
AD  - College of Food Science and Engineering, Northwest A&F University, Shaanxi, 
      China.
FAU - Li, Guanghui
AU  - Li G
AD  - Food and Bioengineering College, Xuchang University, Xuchang, China.
FAU - Xu, Yunfeng
AU  - Xu Y
AD  - College of Food Science and Engineering, Northwest A&F University, Shaanxi, 
      China.
FAU - Xia, Xiaodong
AU  - Xia X
AD  - College of Food Science and Engineering, Northwest A&F University, Shaanxi, 
      China. foodscixiaodong@yahoo.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160531
PL  - Germany
TA  - Mol Nutr Food Res
JT  - Molecular nutrition & food research
JID - 101231818
RN  - 0 (Coumarins)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (MIRN27 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (PPAR gamma)
RN  - 0 (Protective Agents)
RN  - 0 (oxidized low density lipoprotein)
RN  - 1143-70-0 (3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-one)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - EC 1.14.13.39 (NOS3 protein, human)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
SB  - IM
MH  - Cell Adhesion/drug effects
MH  - Cell Line
MH  - Coumarins/*pharmacology
MH  - Endothelium, Vascular/*drug effects/metabolism/physiopathology
MH  - Humans
MH  - L-Lactate Dehydrogenase/metabolism
MH  - Lipoproteins, LDL/*metabolism
MH  - MAP Kinase Signaling System/drug effects
MH  - MicroRNAs/*metabolism
MH  - Monocytes/drug effects
MH  - Nitric Oxide/metabolism
MH  - Nitric Oxide Synthase Type III/metabolism
MH  - PPAR gamma/genetics/*metabolism
MH  - Protective Agents/pharmacology
OTO - NOTNLM
OT  - Atherosclerosis
OT  - ERK signal pathway
OT  - Endothelial dysfunction
OT  - MicroRNA-27
OT  - Urolithin A
EDAT- 2016/04/10 06:00
MHDA- 2017/11/29 06:00
CRDT- 2016/04/10 06:00
PHST- 2015/10/22 00:00 [received]
PHST- 2016/03/18 00:00 [revised]
PHST- 2016/03/28 00:00 [accepted]
PHST- 2016/04/10 06:00 [entrez]
PHST- 2016/04/10 06:00 [pubmed]
PHST- 2017/11/29 06:00 [medline]
AID - 10.1002/mnfr.201500827 [doi]
PST - ppublish
SO  - Mol Nutr Food Res. 2016 Sep;60(9):1933-43. doi: 10.1002/mnfr.201500827. Epub 2016 
      May 31.